Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Defenses against SARS-CoV-2 variants
Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV
Топ-30
Журналы
|
5
10
15
20
25
30
35
|
|
|
bioRxiv
35 публикаций, 19.13%
|
|
|
Nature Communications
8 публикаций, 4.37%
|
|
|
Frontiers in Immunology
8 публикаций, 4.37%
|
|
|
Science
6 публикаций, 3.28%
|
|
|
PLoS Pathogens
5 публикаций, 2.73%
|
|
|
Science Translational Medicine
5 публикаций, 2.73%
|
|
|
Viruses
4 публикации, 2.19%
|
|
|
iScience
4 публикации, 2.19%
|
|
|
Cell
3 публикации, 1.64%
|
|
|
Nature Immunology
3 публикации, 1.64%
|
|
|
Cell Reports
3 публикации, 1.64%
|
|
|
Immunity
3 публикации, 1.64%
|
|
|
International Journal of Biological Macromolecules
3 публикации, 1.64%
|
|
|
Science immunology
3 публикации, 1.64%
|
|
|
medRxiv
3 публикации, 1.64%
|
|
|
International Journal of Molecular Sciences
2 публикации, 1.09%
|
|
|
Biomolecules
2 публикации, 1.09%
|
|
|
npj Vaccines
2 публикации, 1.09%
|
|
|
Cell Research
2 публикации, 1.09%
|
|
|
Nature
2 публикации, 1.09%
|
|
|
Signal Transduction and Targeted Therapy
2 публикации, 1.09%
|
|
|
Structure
2 публикации, 1.09%
|
|
|
Cell Host and Microbe
2 публикации, 1.09%
|
|
|
PLoS ONE
2 публикации, 1.09%
|
|
|
Journal of Medical Virology
2 публикации, 1.09%
|
|
|
Journal of Experimental Medicine
2 публикации, 1.09%
|
|
|
Journal of Virology
2 публикации, 1.09%
|
|
|
Science advances
2 публикации, 1.09%
|
|
|
Current Pharmaceutical Design
1 публикация, 0.55%
|
|
|
Biochemical Society Transactions
1 публикация, 0.55%
|
|
|
5
10
15
20
25
30
35
|
Издатели
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
39 публикаций, 21.31%
|
|
|
openRxiv
38 публикаций, 20.77%
|
|
|
Springer Nature
30 публикаций, 16.39%
|
|
|
American Association for the Advancement of Science (AAAS)
16 публикаций, 8.74%
|
|
|
MDPI
14 публикаций, 7.65%
|
|
|
Frontiers Media S.A.
9 публикаций, 4.92%
|
|
|
Public Library of Science (PLoS)
8 публикаций, 4.37%
|
|
|
Wiley
8 публикаций, 4.37%
|
|
|
American Chemical Society (ACS)
4 публикации, 2.19%
|
|
|
Taylor & Francis
3 публикации, 1.64%
|
|
|
American Society for Microbiology
3 публикации, 1.64%
|
|
|
Bentham Science Publishers Ltd.
2 публикации, 1.09%
|
|
|
Oxford University Press
2 публикации, 1.09%
|
|
|
Rockefeller University Press
2 публикации, 1.09%
|
|
|
Portland Press
1 публикация, 0.55%
|
|
|
LLC Numicom
1 публикация, 0.55%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 публикация, 0.55%
|
|
|
Annual Reviews
1 публикация, 0.55%
|
|
|
Ovid Technologies (Wolters Kluwer) - Medknow Publications
1 публикация, 0.55%
|
|
|
5
10
15
20
25
30
35
40
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.